Mauricio Burotto - Researcher Profile

Publications

1 shown

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Toni K. Choueiri , Thomas Powles , Mauricio Burotto +28 more

Nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free survival, overall survival, and likelihood of response in patients with prev...

2021 New England Journal of Medicine 1584 citations

Frequent Co-Authors

Bogdan Żurawski

Víctor Manuel Oyervides-Juárez

Hospital Universitario Dr José Eleuterio Gonzalez

Researcher Info

h-index: 1
Publications: 1
Citations: 1,584

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-7150-4033

Impact Metrics

h-index 1

h-index: Number of publications with at least h citations each.

Publications

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Frequent Co-Authors

Toni K. Choueiri

Thomas Powles

Bernard Escudier

María T. Bourlon